Search This Blog

Thursday, November 2, 2023

Novo Nordisk shrugs off supply issues with record sales

 Sales of Novo Nordisk’s fast-growing GLP-1 agonist drugs for diabetes and obesity may be held back by supply constraints, but feverish demand is still driving strong growth.

The Danish pharma group reported sales growth of 33% in the first nine months of the year to DKK 166.4 billion ($23.7 billion), driven by a 58% rise in sales of once-weekly diabetes injection Ozempic (semaglutide) to DKK 65.7 billion.

Meanwhile, obesity therapy Wegovy, based on a higher dose of semaglutide, saw sales rocket from DKK 3.7 billion in the first nine months of 2022 to almost DKK 22 billion, helping Novo Nordisk to a record operating profit up 37% to DKK 75.8 billion.

The performance is remarkable as both Ozempic and Wegovy are subject to rationing at the moment as demand outstrips supply, becoming sought after for their weight-loss properties. In some countries, there are reports of diabetics struggling to access Ozempic as supplies are being diverted for use by overweight patients.

Novo Nordisk is predicting further strong growth but said its forecasts reflect “continued periodic supply constraints and related drug shortage notifications across a number of products and geographies” that will last into 2024 at least.

The company is working to boost “internal and external” manufacturing capacity for Wegovy but said access to lower starting doses of the drug will continue to be restricted to eke out available supplies.

Demand for both drugs is likely to be lifted even further by new outcomes data showing that Ozempic can reduce the risk of chronic kidney disease in patients with type 2 diabetes, while Wegovy has been shown to reduce cardiovascular complications by 20% in overweight or obese patients who had underlying cardiovascular disease, but no prior history of diabetes.

Applications to add the cardiovascular claim to Wegovy’s label have been filed in the US and Europe, and the filing has been fast-tracked by the FDA. The Ozempic CKD data, meanwhile, is heading for a final readout next year, with regulatory submissions likely following thereafter.

There had been hopes for good news on the shortages in the update, but the robust growth reassured investors and shares in Novo Nordisk rose sharply after the third-quarter results update.

In other R&D news, Novo Nordisk said it had started phase 1 testing of a once-weekly subcutaneous amycretin injection, another obesity candidate, monoclonal antibody ANGPTL3i for cardiovascular disease, and a STAT3-targeting RNA interference candidate for cancer.

Lilly’s Mounjaro also growing strongly

Also this morning, Eli Lilly reported big sales gains for its dual GLP-1/GIP agonist Mounjaro (tirzepatide) for diabetes, up more than 200% to just under $3 billion in the first nine months of the year – including $1.4 billion in the third quarter alone – ahead of an anticipated filing for obesity.

The drug helped Lilly to a 37% increase in third-quarter revenues to %9.5 billion, although there were signs of pressure on Ozempic rival Trulicity (dulaglutide), down 10% in the third quarter to $1.67 billion. On the plus side, CDK4/6 inhibitor Verzenio (abemaciclib) grew 68% in the three-month period to top $1 billion, fuelled by expanded use in early-stage breast cancer.

https://pharmaphorum.com/news/novo-nordisk-shrugs-supply-issues-record-sales

GSK grabs early lead in RSV vaccine race with Pfizer

 It is still very early days, but GSK’s respiratory syncytial virus (RSV) Arexvy seems to have flown out of the traps more quickly than Pfizer’s rival shot Abrysvo in the first weeks since they reached the market.

GSK chief executive Emma Walmsley (pictured above), who described the launch of Arexvy as “outstanding”, is already talking about the vaccine’s potential to become a blockbuster product in its first year.

GSK is now predicting full-year 2023 sales of £900 million to £1 billion ($1 to $1.2 billion), after recording £709 million in turnover for the third quarter.

The company said the expectation is that Arexvy sales will “track in line” with high-dose flu vaccines, which are a cornerstone of its vaccines business.

Abrysvo’s launch was also very respectable, with Pfizer reporting third-quarter revenues of $375 million for the vaccine earlier this week. For now, however, GSK’s jab – which was the first to launch in the US – seems to be winning the tussle in the market for jabs used to protect older adults.

Pfizer’s product has the advantage of approval for use in pregnant women to protect their babies from RSV disease, an indication that GSK abandoned for Arexvy due to safety concerns. That likely came too late in the day to have a big impact on its third-quarter sales, though, as it wasn’t cleared for that use by the Centres for Disease Control and Prevention (CDC) until late September.

Pfizer CEO Albert Bourla said earlier this week that dual indication could be important “as many customers have indicated to us that protecting both populations with one vaccine is desirable and a competitive advantage for Abrysvo.”

Third-quarter sales were always expected to be high given the need to stock supplies ahead of the coming RSV season, which starts in the autumn, but the performance of both products suggests that a sizeable and sustainable market for vaccines used in older adults is feasible, backing up predictions that the market eventually could be worth up to $10 billion a year worldwide.

In the US alone, there are approximately 80 million adults over age 60 who are eligible for RSV vaccination, along with around 1.5 million pregnant women who could be candidates for maternal immunisation.

GSK is also trying to tip the balance in its favour by extending the label for Arexvy into a younger age group of 50 to 59-year-olds with underlying health conditions that could make them vulnerable to RSV disease and is preparing to file for approval of that indication in the US.

The two leaders may not have the market to themselves for very long, however, as competing candidates from Moderna and Bavarian Nordic are in late-stage development.

https://pharmaphorum.com/news/gsk-grabs-early-lead-rsv-vaccine-race-pfizer

Rick Scott: It's Time To Unite Behind Donald Trump

 An open border with terrorists, criminals, and drugs pouring into our country. A botched withdrawal from Afghanistan that stranded thousands of Americans and our allies behind enemy lines, left billions of dollars' worth of U.S. military equipment in the hands of terrorists, and took the lives of 13 heroic U.S. service members. A military that is more focused on pronouns than lethality. The complete destruction of women's sports. People getting paid not to go to work. Crime rampant in major U.S. cities and people who break laws no longer being held accountable. A nation where criminals have more rights than victims. Appeasement of Xi Jinping and murderous dictators eroding freedom, democracy, and stability around the world. And now, Israel is under attack and at war after Joe Biden reduced oil sanctions and unfroze $6 billion for the Iranian regime. Israelis and Americans have been tortured and killed and are still being held hostage at the hands of Iran-financed terrorists.

Forty years ago, Ronald Reagan campaigned for reelection with the phrase "morning in America." It was a message that resonated with Americans from all walks of life who were recovering from the malaise of the Jimmy Carter years. Ronald Reagan wouldn't recognize our country today.

I am often asked whether this is the beginning of the end of America. It will be, if we stop fighting and cede our country to the incompetent, radical Democrats who are destroying the fundamental values that make America great. We of course do not even know if Joe Biden is lucid enough to be aware that his administration is destroying America. Biden's presidency has become an embarrassment to his political party and to our entire nation.

I am optimistic that we can return America to its rightful position of economic and military strength and the undisputed moral leader of the free world, but only with strong leadership in the White House. That is why I support my friend President Donald J. Trump to be the 47th president of the United States and encourage every Republican to unite behind his efforts to win back the White House.

It's time for the Republican Party to come together, behind one candidate, and declare with one voice that we are united in our efforts to defeat Joe Biden and rescue America.

I know most of the candidates running for president, and I respect their decision to put themselves through this very difficult process. They've made their case to voters, laid out their agendas and their plans, and told their stories. Make no mistake: every single one of them would be a better president than Joe Biden. But Republican voters are making their voices heard loud and clear. They want to return to the leadership of Donald Trump.

President Trump will be our nominee because America was safer and more prosperous when he led our nation. Our economy was booming, and we were achieving energy independence. He took on Communist China and stood up to dictators in Latin America. He did more for Israel than any other president in our history, bringing stability and peace in the Middle East through the Abraham Accords, while Joe Biden is undoing all the work his administration accomplished.

As governor and senator, I worked hand in hand with President Trump to accomplish great things for Florida. When Donald Trump was in the White House, Florida had a partner in the Oval Office. That's not true anymore under President Biden. President Trump and I accomplished a lot together, and we have so much more work to do to fix what's been broken by President Biden.

Biden has failed to stand up to the illegitimate communist regimes in Cuba, Venezuela, and Nicaragua. He has failed to secure our border and protect Florida jobs and our agriculture industry from unfair and illegal trade practices in Mexico. This week, I asked FBI Director Christopher Wray if the country was safer under Biden and his silence was deafening. I know Donald Trump will work with us to fix these problems.

I'd never demand or even ask that another candidate drop out of a political contest. That's a decision for every candidate to make for themselves. But I'm supporting Donald Trump for president because the stakes are too high. The future of our country depends on our ability to come together and throw Joe Biden and these radical Democrats, who are intent on destroying our country, out of office.

Here's the honest truth. It's not morning in America today. It's midnight in America. In my view there is one person running who has the strength to bring America back, who is well-positioned to win the Republican primary, and who will win the general election. And that is why I am supporting Donald Trump for president.

Rick Scott, a Republican, is the junior U.S. Senator from Florida.

https://www.newsweek.com/rick-scott-its-time-unite-behind-donald-trump-opinion-1840060

Thyroid Hormones May Increase Risk of Cognitive Disorders in Older Adults

 Patients age 65 and older who receive thyroid hormone therapy and experience low thyrotropin are at increased risk for dementia and other cognitive problems, according to new research published October 23 in JAMA Internal Medicine.

The study found that these patients with thyrotoxicosis had a higher likelihood of incident cognitive disorder (adjusted hazard ratio (aHR), 1.39; 95% CI, 1.18 - 1.64; P <  .001). Broken down between internal and external causes of thyrotoxicosis, exogenous thyrotoxicosis continued to be a significant risk factor (aHR, 1.34: 95% CI, 1.10 - 1.63; P = .003), while endogenous thyrotoxicosis did not show a statistically significant risk estimates (aHR, 1.38; 95% CI, 0.96 - 1.98; P = .08).

The study also found that women were more likely to have low levels of thyrotropin (thyroid-stimulating hormone/TSH) than men and were more likely to be overtreated.

Previous studies looking at the correlation between hyperthyroidism and cognitive disorders often did not include participants who were already taking thyroid hormones, according to Jennifer S. Mammen, MD, PhD, assistant professor of medicine at the Asthma and Allergy Center at John Hopkins University School of Medicine in Baltimore and the senior author of the study.

"The fact that we see the signal both in people who are being overtreated with thyroid hormone and in people who have endogenous hyperthyroidism is one way that we think that this supports the fact that it's not just confounding, it's not just bias," Mammen said. "There's two different sources of hyperthyroidism, and they're both showing the same relationship."

In the study, Mammen and colleagues analyzed electronic health records for patients aged 65 years and older who received primary care in the Johns Hopkins Community Physicians Network over a 10-year period starting in 2014. Patients had to have a minimum of two visits 30 days apart. None had a history of low TSH levels or cognitive disorder diagnoses within 6 months of their first doctor visit.

More than 65,000 patients were included in the study. Slightly more than half (56%) were female, almost 70% were White, 19.3% were Black, 4.6% were Asian, and 0.4% were American Indian. Almost 25,000 low TSH measurements among 2710 patients were recorded during the study period. The majority of low TSH measurements were exogenous (14,875), followed by origins of unknown cause (5833), and endogenous (4159).

During the follow-up period, 7.2% (4779) patients received a new cognitive disorder diagnosis, which was dementia in 77% of cases.

Mammen said primary care physicians should carefully consider whether thyroid hormone therapy is necessary for older patients, and, if so, great care should be taken to avoid overtreatment.

"This is yet another reason for us to be vigilant about not overtreating people with thyroid hormone, especially in older adults," Mammen said. "We already know that atrial fibrillation rates are increased in people who are hyperthyroid. We know that fracture and osteoporosis is affected by hyperthyroidism. And now we also have an association with higher rates of cognitive disorders."

Taking a cautious approach to prescribing thyroid hormone therapy for older patients is paramount, according to Jean Chen, MD, partner at Texas Diabetes & Endocrinology, who was not affiliated with the study.

"All medical providers need to be aware that the 65 and older population does not need to be treated as aggressively with their thyroid hormone," Chen said. "We are finding more and more complications from overtreatment rather than benefit in this population."

Often, older patients may complain of symptoms such as constipation, feeling cold, or tiredness, which can be symptoms of hypothyroidism. But these symptoms could also be from anemia, vitamin deficiencies, depression, perimenopause, menopauseinsulin resistance, and sleep apnea. If necessary, Chen recommends primary care physicians consult with an endocrinologist regarding a possible treatment plan and making a differential diagnosis.

In addition, Chen said other studies have shown that treating patients with thyroid hormone either did not resolve the condition or negatively impacted anxiety, muscle strength, and bone density, or it increased the risk for arrhythmia. Therefore, it’s important to weight the risks vs the benefits.

"There's so much gray zone here," Chen said.

The study was supported by the Richman Family Precision Medicine Center of Excellence in Alzheimer’s Disease, the Richman Family Foundation, the Rick Sharp Alzheimer’s Foundation, the Sharp Family Foundation, among others. The work was also supported by grants from the National Institutes of Health.

Co-author Constantine Lyketsos, MD, MPH, reports personal fees from Karuna, MapLight Therapeutics, Axsome Therapeutics, GIA, GW Research Limited, Merck, EXCIVA GmbH, Otsuka, IntraCellular Therapies, and Medesis Pharma for consulting for treatment development in Alzheimer's disease outside the submitted work. No other disclosures were reported.

JAMA Internal Med. Published online October 23, 2023. Abstract  

https://www.medscape.com/viewarticle/998036

Strength Training Promotes Knee Health, Lowers OA Risk

 Strength training at any point in life is associated with a lower risk of knee pain and osteoarthritis, contrary to persistent assumptions of adverse effects.

METHODOLOGY:

  • Researchers reviewed data on strength training and knee pain from 2607 adults. They used the Historical Physical Activity Survey Instrument to assess the impact of strength training during four periods (ages 12–18 years, 19–34 years, 3549 years, and 50 years and older).

  • The participants were enrolled in the Osteoarthritis Initiative, a multicenter, prospective, longitudinal study; 44% were male, the average age was 64.3 years, and the mean body mass index was 28.5 kg/m2.

  • Strength training was defined as those exposed and not exposed, as well as divided into low, medium, and high tertiles for those exposed; a total of 818 individuals were exposed to strength training, and 1789 were not exposed to strength training.

  • The primary outcomes were frequent knee pain, radiographic OA (ROA), and symptomatic radiographic OA (SOA).

TAKEAWAY:

  • The study is the first to examine the effect of strength training on knee health in a community population sample not selected for a history of elite weight lifting.

  • Overall, strength training at any point in life was associated with lower incidence of frequent knee pain, ROA, and SOA, compared with no strength training (odds ratios, 0.82, 0.83, and 0.77, respectively).

  • When separated by tertiles, only the high-exposure group had significantly reduced odds of frequent knee pain, ROA, and SOA, with odds ratios of 0.74, 0.70, and 0.69, respectively; a dose-response relationship appeared for all three conditions, with the lowest odds ratios in the highest strength training exposure groups.

  • Findings were similar for different age ranges, but the association between strength training and less frequent knee pain, less ROA, and less SOA was strongest in the older age groups.

IN PRACTICE:

"Our findings support the idea that the medical community should proactively encourage more people to participate in strength training to help reduce their risk of osteoarthritis and other chronic conditions," the researchers write.

SOURCE:

The study, with first author Grace H. Lo, MD, of Baylor College of Medicine, Houston, Texas, and colleagues, was published on October 23 in Arthritis and Rheumatology.

LIMITATIONS:

The observational design and self-selected study population of strength training participants might bias the results, including participants' recall of their activity level levels and changes in exercise trends over time; more research is needed to explore associations between strength training and knee OA among those who started strength training at a younger age.

DISCLOSURES:

The study was funded in part by the VA Health Services Research and Development Center for Innovations in Quality, Effectiveness, and Safety at the Michael E. DeBakey VA Medical Center, Houston, and by donations to the Tupper Research Fund at Tufts Medical Center. The Osteoarthritis Initiative is supported by the National Institutes of Health; private funding partners include Merck Research Laboratories, Novartis, GlaxoSmithKline, and Pfizer. Three authors report having financial relationships with multiple pharmaceutical companies.

https://www.medscape.com/viewarticle/998025

Russian Reshipping Service ‘SWAT USA Drop’ Exposed

 

The login page for the criminal reshipping service SWAT USA Drop.

One of the largest cybercrime services for laundering stolen merchandise was hacked recently, exposing its internal operations, finances and organizational structure. Here’s a closer look at the Russia-based SWAT USA Drop Service, which currently employs more than 1,200 people across the United States who are knowingly or unwittingly involved in reshipping expensive consumer goods purchased with stolen credit cards.

Among the most common ways that thieves extract cash from stolen credit card accounts is through purchasing pricey consumer goods online and reselling them on the black market. Most online retailers grew wise to these scams years ago and stopped shipping to regions of the world most frequently associated with credit card fraud, including Eastern Europe, North Africa, and Russia.

But such restrictions have created a burgeoning underground market for reshipping scams, which rely on willing or unwitting residents in the United States and Europe to receive stolen goods and relay them to crooks living in the embargoed areas.

Services like SWAT are known as “Drops for stuff” on cybercrime forums. The “drops” are people who have responded to work-at-home package reshipping jobs advertised on craigslist.com and job search sites. Most reshipping scams promise employees a monthly salary and even cash bonuses. In reality, the crooks in charge almost always stop communicating with drops just before the first payday, usually about a month after the drop ships their first package.

The packages arrive with prepaid shipping labels that are paid for with stolen credit card numbers, or with hijacked online accounts at FedEx and the US Postal Service. Drops are responsible for inspecting and verifying the contents of shipments, attaching the correct shipping label to each package, and sending them off via the appropriate shipping company.

SWAT takes a percentage cut (up to 50 percent) where “stuffers” — thieves armed with stolen credit card numbers — pay a portion of each product’s retail value to SWAT as the reshipping fee. The stuffers use stolen cards to purchase high-value products from merchants and have the merchants ship the items to the drops’ address. Once the drops receive and successfully reship the stolen packages, the stuffers then sell the products on the local black market.

The SWAT drop service has been around in various names and under different ownership for almost a decade. But in early October 2023, SWAT’s current co-owner — a Russian-speaking individual who uses the handle “Fearlless” — took to his favorite cybercrime forum to lodge a formal complaint against the owner of a competing reshipping service, alleging his rival had hacked SWAT and was trying to poach his stuffers and reshippers by emailing them directly.

Milwaukee-based security firm Hold Security shared recent screenshots of a working SWAT stuffer’s user panel, and those images show that SWAT currently lists more than 1,200 drops in the United States that are available for stuffers to rent. The contact information for Kareem, a young man from Maryland, was listed as an active drop. Contacted by KrebsOnSecurity, Kareem agreed to speak on condition that his full name not be used in this story.

A SWAT panel for stuffers/customers. This page lists the rules of the service, which do not reimburse stuffers for “acts of god,” i.e. authorities seizing stolen goods or arresting the drop.

Kareem said he’d been hired via an online job board to reship packages on behalf of a company calling itself CTSI, and that he’s been receiving and reshipping iPads and Apple watches for several weeks now. Kareem was less than thrilled to learn he would probably not be getting his salary on the promised payday, which was coming up in a few days.

Kareem said he was instructed to create an account at a website called portal-ctsi[.]com, where each day he was expected to log in and check for new messages about pending shipments. Anyone can sign up at this website as a potential reshipping mule, although doing so requires applicants to share a great deal of personal and financial information, as well as copies of an ID or passport matching the supplied name.

A SWAT panel for stuffers/customers, listing hundreds of drops in the United States by their status. “Going to die” are those who are about to be let go without promised payment, or who have quit on their own.

On a suspicion that the login page for portal-ctsi[.]com might be a custom coding job, KrebsOnSecurity selected “view source” from the homepage to expose the site’s HTML code. Grabbing a snippet of that code (e.g., “smarty/default/jui/js/jquery-ui-1.9.2.min.js”) and searching on it at publicwww.com reveals more than four dozen other websites running the same login panel. And all of those appear to be geared toward either stuffers or drops.

In fact, more than half of the domains that use this same login panel actually include the word “stuffer” in the login URL, according to publicwww. Each of the domains below that end in “/user/login.php” are sites for active and prospective drops, and each corresponds to a unique fake company that is responsible for managing its own stable of drops:

lvlup-store[.]com/stuffer/login.php
personalsp[.]com/user/login.php
destaf[.]com/stuffer/login.php
jaderaplus[.]com/stuffer/login.php
33cow[.]com/stuffer/login.php
panelka[.]net/stuffer/login.php
aaservice[.]net/stuffer/login.php
re-shipping[.]ru/stuffer/login.php
bashar[.]cc/stuffer/login.php
marketingyoursmall[.]biz/stuffer/login.php
hovard[.]xyz/stuffer/login.php
pullback[.]xyz/stuffer/login.php
telollevoexpress[.]com/stuffer/login.php
postme[.]today/stuffer/login.php
wint-job[.]com/stuffer/login.php
squadup[.]club/stuffer/login.php
mmmpack[.]pro/stuffer/login.php
yoursmartpanel[.]com/user/login.php
opt257[.]org/user/login.php
touchpad[.]online/stuffer/login.php
peresyloff[.]top/stuffer/login.php
ruzke[.]vodka/stuffer/login.php
staf-manager[.]net/stuffer/login.php
data-job[.]club/stuffer/login.php
logistics-services[.]org/user/login.php
swatship[.]club/stuffer/login.php
logistikmanager[.]online/user/login.php
endorphine[.]world/stuffer/login.php
burbon[.]club/stuffer/login.php
bigdropproject[.]com/stuffer/login.php
jobspaket[.]net/user/login.php
yourcontrolboard[.]com/stuffer/login.php
packmania[.]online/stuffer/login.php
shopping-bro[.]com/stuffer/login.php
dash-redtag[.]com/user/login.php
mnger[.]net/stuffer/login.php
begg[.]work/stuffer/login.php
dashboard-lime[.]com/user/login.php
control-logistic[.]xyz/user/login.php
povetru[.]biz/stuffer/login.php
dash-nitrologistics[.]com/user/login.php
cbpanel[.]top/stuffer/login.php
hrparidise[.]pro/stuffer/login.php
d-cctv[.]top/user/login.php
versandproject[.]com/user/login.php
packitdash[.]com/user/login.php
avissanti-dash[.]com/user/login.php
e-host[.]life/user/login.php
pacmania[.]club/stuffer/login.php

Why so many websites? In practice, all drops are cut loose within approximately 30 days of their first shipment — just before the promised paycheck is due. Because of this constant churn, each stuff shop operator must be constantly recruiting new drops. Also, with this distributed setup, even if one reshipping operation gets shut down (or exposed online), the rest can keep on pumping out dozens of packages a day.

2015 academic study (PDF) on criminal reshipping services found the average financial hit from a reshipping scheme per cardholder was $1,156.93. That study looked into the financial operations of several reshipping schemes, and estimated that approximately 1.6 million credit and debit cards are used to commit at least $1.8 billion in reshipping fraud each year.

It’s not hard to see how reshipping can be a profitable enterprise for card crooks. For example, a stuffer buys a stolen payment card off the black market for $10, and uses that card to purchase more than $1,100 worth of goods. After the reshipping service takes its cut (~$550), and the stuffer pays for his reshipping label (~$100), the stuffer receives the stolen goods and sells them on the black market in Russia for $1,400. He has just turned a $10 investment into more than $700. Rinse, wash, and repeat.

The breach at SWAT exposed not only the nicknames and contact information for all of its stuffers and drops, but also the group’s monthly earnings and payouts. SWAT apparently kept its books in a publicly accessible Google Sheets document, and that document reveals Fearlless and his business partner each routinely made more than $100,000 every month operating their various reshipping businesses.

The exposed SWAT financial records show this crime group has tens of thousands of dollars worth of expenses each month, including payments for the following recurring costs:

-advertising the service on crime forums and via spam;
-people hired to re-route packages, usually by voice over the phone;
-third-party services that sell hacked/stolen USPS/Fedex labels;
-“drops test” services, contractors who will test the honesty of drops by sending them fake jewelry;
-“documents,” e.g. sending drops to physically pick up legal documents for new phony front companies.

The spreadsheet also included the cryptocurrency account numbers that were to be credited each month with SWAT’s earnings. Unsurprisingly, a review of the blockchain activity tied to the bitcoin addresses listed in that document shows that many of them have a deep association with cybercrime, including ransomware activity and transactions at darknet sites that peddle stolen credit cards and residential proxy services.

The information leaked from SWAT also has exposed the real-life identity and financial dealings of its principal owner — Fearlless, a.k.a. “SwatVerified.” We’ll hear more about Fearlless in Part II of this story. Stay tuned.

https://krebsonsecurity.com/2023/11/russian-reshipping-service-swat-usa-drop-exposed/

China's Largest Memory Chip Maker Forced To Raise Capital Due To U.S. Blacklists

 It appears as though Washington's chip controls on China are starting to make a profound impact.

Last December Washington added Yangtze Memory Technologies Corp. to its trade blacklist and now the company, China's largest memory chip maker, is being forced to raise "billions of dollars" in new capital after burning through $7 billion over the past year, FT has reported

The company is also prohibited from procuring U.S. equipment to manufacture its chips, the report says. While Financial Times was unable to confirm the exact amount the company had to raise, they reported it was "equivalent to billions of dollars".

The Wuhan-based YMTC is central to the nation's semiconductor self-sufficiency ambition. Yet, since last fall, U.S. restrictions have limited its access to advanced chip tech. After a $7bn capital boost from backers like China's "Big Fund" last year, the company has rapidly expended funds on equipment and new components.

This led to a new fundraising round, which saw strong domestic investor interest. This support came even before tighter U.S. export controls, indicating a domestic show of unity against U.S. limitations, the report said. 

One government official that's close to the company told Financial Times: "“YMTC is following in Huawei’s footsteps in bringing together the Chinese semiconductor industry to cope with the challenges of US pressure."

“If Chinese companies have equipment that can be used, [YMTC] will use it. If not, it will see if countries other than the US can sell to it. If that doesn’t work, YMTC will develop it together with the supplier,” one investor said.

The company is expected to procure equipment from Chinese suppliers while also using some Japanese, South Korean and European vendors.

YMTC collaborated with Chinese firms Naura and AMEC to enhance etching tech, key to chip layering and cost-effective storage performance, insiders noted. Between January to August, local chipmakers awarded nearly 50% of equipment tenders to Chinese companies, as per a recent Huatai Securities analysis.

But on Chinese chipmaker concluded to FT“The ones that can be quickly replaced by Chinese equipment are less technically challenging tools. The real challenge is to make the advanced ones.”

https://www.zerohedge.com/markets/chinas-largest-memory-chip-maker-forced-raise-capital-due-us-blacklists